Polyanhydride nanoparticle platforms present an enhanced safety profile compared to Alum and IFA. Combined with the enhanced antigen stabilization and pathogen mimicking capabilities of this vaccine platform, this technology provides a viable alternative adjuvant for next generation vaccines.
展开▼
